Neutropenia and neoplasia: an overview of the pharmacoeconomics of sargramostim in cancer therapy
- 1 July 1997
- journal article
- Published by Elsevier in Clinical Therapeutics
- Vol. 19 (4) , 847-865
- https://doi.org/10.1016/s0149-2918(97)80108-7
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- FilgrastimPharmacoEconomics, 1996
- The Costs of Treating Febrile Neutropenia in Patients with Malignant Blood DisordersPharmacoEconomics, 1994
- Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor after Autologous Bone Marrow Transplantation for Lymphoid CancerPharmacoEconomics, 1994
- Recombinant Granulocyte-Macrophage Colony-Stimulating Factor (rGM-CSF)PharmacoEconomics, 1994
- The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapyEuropean Journal Of Cancer, 1993
- Recombinant Granulocyte-Macrophage Colony-Stimulating Factor (rGM-CSF)Drugs, 1992
- Dose-intensive treatment of breast cancer supported by granulocyte-macrophage colony-stimulating factor (GM-CSF)Breast Cancer Research and Treatment, 1991
- Cost Effectiveness of Bone Marrow Transplantation in Acute Nonlymphocytic LeukemiaNew England Journal of Medicine, 1989
- Infection in cancer patients: A continuing associationThe American Journal of Medicine, 1986
- Fungal infections complicating acute leukemiaJournal of Chronic Diseases, 1966